BiomarkersHuman trial
Variations in Plasma p ‐tau217 by Sociodemographic Factors Across World Regions in a Preclinical AD Clinical Trials Program: the AHEAD 3‐45 Study
AAIC 2025 Abstract
Abstract
Background: The AHEAD 3‐45 Study, a preclinical Alzheimer’s Disease (AD) trials program testing lecanemab in asymptomatic individuals with biomarker evidence of disease, completed its randomization October 2024.
The paper
Doris P. Molina‐Henry, Rema Raman, Andy Liu, the AHEAD 3‐45 Study Team
Show 9 more authors
Oliver Langford, Joel B. Braunstein, Shobha Dhadda, Michael C. Irizarry, Joshua D. Grill, Keith A. Johnson, Robert A. Rissman, Paul S. Aisen, Reisa Anne Sperling,University of Southern California
AAIC 2025 Abstract · 23 Dec 2025 · CC BY
Presented at AAIC 2025
